Warning: This security is no longer trading.
Celgene Corporation has completed the acquisition of Juno Therapeutics, Inc.
Juno Therapeutics, Inc. (JUNO): Price and Financial Metrics
JUNO Price/Volume Stats
| Current price | $86.96 | 52-week high | $87.01 |
| Prev. close | $86.87 | 52-week low | $19.62 |
| Day low | $86.90 | Volume | 3,696,100 |
| Day high | $87.01 | Avg. volume | 5,484,542 |
| 50-day MA | $71.86 | Dividend yield | N/A |
| 200-day MA | $46.70 | Market Cap | 10.10B |
JUNO Stock Price Chart Interactive Chart >
Juno Therapeutics, Inc. (JUNO) Company Bio
Juno Therapeutics is a biopharmaceutical company developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. The company was founded in 2013 and is based in Seattle, Washington.
JUNO Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...